GET DAILY SIGNALSSpyre Therapeutics (SYRE) Widens Q3 Net Loss to $96.1 Million as Pipeline Spending Accelerates
Key Takeaways
- Spyre Therapeutics reported a third quarter 2026 net loss of $96.1 million, widening from $11.2 million in the same period a year earlier.
- Net loss per common share came in at $0.94, wider than the consensus estimate of roughly $0.78 per share.
- Research and development (R&D) expenses nearly doubled to $89.2 million, driven by higher manufacturing costs and clinical trial activity.
- As a clinical-stage company, Spyre recorded no product revenue; cash, cash equivalents, and marketable securities totaled $1,071.9 million at quarter end.
- Pro forma cash of about $1,467.9 million, reflecting an October public offering, is expected to fund operations into the second half of 2029.
- For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated ticker pages.
- Investors looking for AI-driven trading ideas can also explore Trending AI Robots.
Why the Earnings Context Matters
Spyre Therapeutics is a clinical-stage biotechnology company focused on inflammatory bowel disease (IBD) and other immune-mediated conditions. Because it has no approved products, its earnings reports center less on revenue and more on spending discipline, cash runway, and the advancement of its pipeline. The third quarter of 2026 arrived at a pivotal moment, with the company actively enrolling multiple combination candidates in its SKYLINE trial and initiating new Phase 2 studies. For investors, the key questions heading into the release were whether rising development costs were matched by clinical momentum and whether the balance sheet remained strong enough to support these programs through meaningful data readouts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results Breakdown
Spyre Therapeutics reported a net loss of $96.1 million for the third quarter of 2026, compared with $11.2 million in the prior-year period. On a per-share basis, the net loss per common share was $0.94, wider than the consensus estimate of approximately $0.78. The sharp widening largely reflected a surge in R&D spending, which climbed to $89.2 million from $45.2 million a year earlier, as well as a decline in other income. General and administrative (G&A) expenses also rose, reaching $16.6 million compared with $11.6 million in the year-ago quarter.
As of September 30, 2026, the company held $1,071.9 million in cash, cash equivalents, and marketable securities. On a pro forma basis, including roughly $378.0 million in net proceeds from an October 2026 underwritten public offering and additional at-the-market sales, cash stood at about $1,467.9 million, supporting an expected runway into the second half of 2029. Net cash used in operating activities was $77.5 million for the quarter.
Market Reaction and Investor Sentiment
As a pre-revenue biotech, Spyre Therapeutics stock tends to react more to pipeline news and balance-sheet strength than to its GAAP loss per share. The wider-than-expected quarterly loss is likely to be viewed in the context of deliberate, front-loaded investment across multiple clinical programs rather than as a sign of operational weakness. The company's substantial cash position, reinforced by the October offering, provides a buffer against dilution concerns in the near term. Still, the sharp increase in quarterly expenses and the decline in other income compared with the prior year may weigh on sentiment as investors assess how efficiently capital is being deployed toward upcoming data readouts.
Forward Outlook and Key Factors to Monitor
Looking ahead, the central story for Spyre Therapeutics remains its clinical pipeline rather than near-term profitability. The company is currently enrolling its SPY120, SPY130, and SPY230 combination candidates in Part B of the SKYLINE trial, with an expected induction read-out in 2027. These programs pair long-acting antibodies targeting key inflammatory pathways, an approach aimed at improving convenience and efficacy for patients with IBD.
Investors should also monitor the SKYLIGHT Phase 2 trial of SPY072 in hidradenitis suppurativa (HS), a chronic inflammatory skin condition. The study is designed as a proof-of-concept for the company's internal SPY772 combination program, with topline Week 16 results planned for late 2027 or early 2028.
On the financial side, the key variables will be the trajectory of R&D spending as trials expand, the pace of operating cash burn, and how long the strengthened cash position sustains the pipeline. While the reported loss widened materially, the extended runway into 2029 gives Spyre room to advance multiple programs before needing additional capital. Watch for trial enrollment updates, data timelines, and any shifts in guidance around expected readouts.
My Experience with Tickeron’s AI Screener
In my own research process, I often turn to Tickeron’s AI Screener when evaluating clinical-stage names like SYRE. It lets me quickly filter biotech peers by fundamentals, volatility, and technical signals, which helps put the quarter’s spending trends into broader industry context without spending hours on manual screens. The tool has become a regular part of how I cross-check pipeline progress against comparable companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SYRE's Stochastic Oscillator remains in overbought zone for 9 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SYRE moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 63 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +7.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.168) is normal, around the industry mean (3.051). P/E Ratio (-51.720) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement